Mesoblast’s Potential Blockbuster Back Pain Therapy Moves Closer as Phase 3 Treatment Completes

Mesoblast completes treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. Results expected mid-2027.